Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.ALEXZA PHARMACEUTICALS, INC.
(a development stage company)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)Three Months EndedSix Months EndedJune 30,June 30,2012201120122011Revenue
$
728$
,258$
2,612$
2,517Operating expenses:Research and development
5,0106,66410,04212,926General and administrative
2,9042,7354,1495,555Total operating expenses
7,9149,39914,19118,481Loss from operations
(7,186)(8,141)(11,579)(15,964)Loss on change in fair value of contingent
consideration liability
200(300)1,200(300)Interest and other income/ (expense), net
409740817Interest expense
(380)(572)(813)(1,174)Net loss
(6,957)(9,006)(10,784)(17,421)Basic and diluted net loss per share
$
(0.58)$
(1.34)$
(1.03)$
(2.74)ALEXZA PHARMACEUTICALS, INC.
(a development stage company)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)June 30,December 31,20122011(1)ASSETSCurrent assets: Cash, cash equivalents and marketable securities
$
8,526$
,903Restricted cash
7,847-Other current assets
52210,649Total current assets
26,89527,552Property and equipment, net
17,87520,425Other noncurrent assets
615628Total assets
$
45,385$
48,605LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITYTotal current liabilities
$
21,216$
34,948Noncurrent liabilities
20,84723,349Total stockholders' (deficit) equity
3,322(9,692)Total liabilities and stockholders' (deficit) equity
$
45,385$
48,605(1) Derive
'/>"/>
SOURCE Alexza Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related medicine technology :1.
Alexza Announces Management Promotions2.
Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.3.
Alexza Announces Reverse Stock Split in Order to Maintain NASDAQ Listing4.
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.5.
Alexza Receives Complete Response Letter for Adasuve™ NDA6.
Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 20127.
NxStage Reports Record Revenue For The Second Quarter Of Fiscal 20128.
InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million9.
diaDexus, Inc. Reports Second Quarter 2012 Financial Results10.
HeartWare Reports Second Quarter 2012 Results11.
Omeros Corporation Reports Second Quarter 2012 Financial Results